SizeRealcan Pharmaceutical (002589.SZ) is a China Health Care company (Pharmaceuticals: Generic) with a market value of $628M, the 3317th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.82 on 6 Nov 2026.
Performance Over six months the shares fell 11.3%, against -21.6% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 6 in its peer set.
Growth Revenue fell 3.9% over the last twelve months (peer median -6.2%); the operating margin is 0.5% (peer median -110.7%).
Valuation It trades at 1.0× enterprise value to sales against a peer median of 34.1× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is -23%, so the hurdle is +41 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.5 points below its cost of capital (5.0% WACC).
Relative performance
Six months, rebased to 100: Realcan Pharmaceutical against the median of its 5 peers (local-currency closes).
Realcan Pharmaceutical financials
Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Performance: 6-month against 1-month return
Up and to the right = strong over both horizons. Realcan Pharmaceutical is the large dot.
Fundamentals: revenue growth against valuation
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Realcan Pharmaceutical is the large dot.
Realcan Pharmaceutical competitors and peer comparison
How Realcan Pharmaceutical compares with its peers
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
Realcan Pharmaceutical against its 5 peers (data as of 6 Nov 2026)
Measure
002589.SZ
Peer median
Rank in peer set
1-month return
-12.7%
-16.0%
3rd highest of 6
6-month return
-11.3%
-21.6%
3rd highest of 6
Distance from 52-week high
-39.9%
-48.7%
2nd highest of 6
Revenue growth (TTM)
-3.9%
-6.2%
3rd highest of 6
Operating margin
0.5%
-110.7%
2nd highest of 5
EV / Sales
1.0×
34.1×
cheapest of 6
Growth the price implies (Req g, 7 yrs)
17.7%
n/a
—
Growth delivered (Del g)
-23.1%
n/a
—
Hurdle (Req g minus delivered)
+40.8 pp
n/a
—
ROIC minus cost of capital
-3.5 pp
-34.7 pp
2nd highest of 5
Peer table
Peer set: Industry: the same industry and sector in any market, nearest in size
Which companies are Realcan Pharmaceutical's closest peers?
The cockpit's peer set: Tibet Duo Rui Pharmaceutical (301075.SZ), Suzhou Ribo Life Science (6938.HK), Zhejiang Shouxiangu Pharmaceutical (603896.SS), Vigonvita Life Sciences (2630.HK), Neuren Pharmaceuticals (NEU.AX).
Is Realcan Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.0× against a peer median of 34.1×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is -23%, so the hurdle is +41 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Realcan Pharmaceutical stock performed?
Over six months to 6 Nov 2026 the shares returned -11.3% against -21.6% for the median peer; over one year -4.1%.